Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084104 | 1.00 | RAB9A (0.65) | RAB9ATP53SMN1; SMN2NPC1CNR1 | |
| SCHEMBL2752539 | 0.88 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1MAPTFAP | |
| SCHEMBL5024303 | 0.86 | RAB9A (0.51) | RAB9ASMN1; SMN2DRD2DRD3HTR2A | |
| SCHEMBL27882705 | 0.84 | DRD2 (0.51) | RAB9ASMN1; SMN2DRD2DRD3HTR2A | |
| SCHEMBL27882706 | 0.84 | DRD2 (0.51) | RAB9ASMN1; SMN2DRD2DRD3HTR2A | |
| SCHEMBL228810 | 0.83 | DRD3 (0.55) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL228811 | 0.83 | DRD3 (0.55) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL227557 | 0.82 | DRD3 (0.54) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL226200 | 0.82 | DRD3 (0.54) | DRD2DRD3HTR2AHTR1ADRD4 | |
| SCHEMBL3087229 | 0.82 | DRD3 (0.54) | CNR1CNR2DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | RAB9A 1751/4885TP53 4845/4885SMN1; SMN2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.